Sanofi Reports long-term follow-up Data for Ipilimumab in Atrial fibrillation

Sanofi today announced long-term follow-up results for ipilimumab in patients with atrial fibrillation. The study demonstrated that ipilimumab demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of atrial fibrillation and support the continued development of ipilimumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.